Dynavax Announces First Quarter 2005 Financial Results Conference Call and Webcast

April 20, 2005 at 12:00 AM EDT
Dynavax Announces First Quarter 2005 Financial Results Conference Call and Webcast

BERKELEY, Calif., April 20, 2005 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) will announce its first quarter 2005 financial results on Thursday, April 28, 2005 at 4:00 p.m. ET.

The announcement will be followed by a live webcast at 5:00 p.m. ET of a discussion by Dynavax Technologies management of first quarter 2005 financial results.

The webcast may be accessed on the Webcast page under Investors on the Dynavax Technologies' website at http://www.dynavax.com .

The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.fulldisclosure.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).

An audio replay of the webcast will be available until May 5, 2005 by dialing 888-286-8010; conference identification number 31364406. International callers can dial 617-801-6888; conference identification number 31364406.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. ISS are being developed in three initial indications: ragweed allergy immunotherapeutic, currently in a Phase 2/3 clinical trial; a Hepatitis B vaccine, currently in a Phase 2/3 clinical trial; and an asthma immunotherapeutic that has completed a Phase 2 exploratory trial.

SOURCE Dynavax Technologies Corporation

Jane M. Green, Ph.D., Vice President, Corporate Communications, of Dynavax Technologies Corporation, +1-510-665-4630, or jgreen@dvax.com